The Week Ahead: Fed...
Health Care: Drugs
AspenBio Pharma Inc. (APPY: NASDAQ)
$0.49 0.01 | 2.51%
06/04/12 - 10:18 AM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -10.21M | -13.34M | -15.52M | -9.57M |
| Operating Gains/Losses | -938.90K | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 38.16K | -25.22K | 15.24K | 4.71K |
| (Increase) Decrease in Inventories | 0.00 | 322.42K | 232.74K | 35.04K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 284.54K | -419.38K | 662.31K | 520.17K |
| (Decrease) Increase In Other Current Liabilities | 30.77K | -222.65K | 167.92K | 1.14M |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 1.61M | 2.47M | 2.29M | 1.70M |
| Net Cash From Continuing Operations | -8.33M | -10.71M | -11.36M | -6.44M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.33M | -10.71M | -11.36M | -6.44M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 2.97M | 5.21M | 7.44M | 12.76M |
| Purchases of Property, Plant & Equipment | -90.10K | -501.41K | -595.95K | -753.17K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -1.04M | -7.63M | -2.31M | -9.91M |
| Other Cash from Investing Activities | -228.16K | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 1.61M | -2.92M | 4.53M | 2.09M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 1.46M | 9.41M | 8.73M | 560.32K |
| Repayment of Long-Term Debt | -673.90K | -236.16K | -350.62K | -777.16K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | -991.88K |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 782.16K | 9.17M | 8.38M | -1.21M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -5.94M | -4.46M | 1.55M | -5.56M |
Portfolios with APPY
- Portfolio NameUser Type
- UserSUPRATRADE-2709091838
- UserBrahmsian's Debt/Equity Por...
- UserBrahmsian's Financially Sou...
- Userdan vosika Portfolio 1
- Usergame on
- Userdreamerl3oi Portfolio 1
- Useremannn Portfolio 1
- UserKBEE Portfolio 1
- UserMoney and Suits Portfolio 1
- UserFly Me To The Moon Monster ...
Latest APPY Headlines from TheStreet
- Biotech Sector Weekly Rewind 11.13.10 | 07:11 am
- Vantage Drilling, First M&F: Volume Movers 07.20.10 | 07:07 am
- AspenBio Finds Fault Afar for Failure 07.20.10 | 06:07 am
- Biotech Stock Mailbag: Spectrum Pharma 06.18.10 | 07:06 am
- Hellenic Telecom, AspenBio Pharma: Midday Volume Plays 06.07.10 | 12:06 pm
- Stock Offerings: Navios Maritime 04.30.10 | 11:04 am
- Biotech Stock Mailbag: AspenBio 04.30.10 | 06:04 am
- ClickSoftware, AspenBio: Early Volume Plays 12.29.09 | 07:12 am
- AspenBio Pharma Prices Public Offering 10.07.09 | 08:10 am
- Biotech News Roundup: Aspen, AMAG, Vertex 08.17.09 | 12:08 pm
Press Releases for APPY
- AspenBio Appoints Diagnostics Industry Veteran Don Hurd As Senior Vice President And Chief Commercial Officer - Business Wire 05.24.12 | 09:05 am
- AspenBio Pharma’s Clinical Study Suggests One-Third Of CT Scans Used To Assess Pediatric And Adolescent Patients At Low Risk For Acute Appendicitis Could Potentially Be Avoided - Business Wire 04.18.12 | 09:04 am
- Results Of 503-Patient Clinical Study Of AspenBio Pharma’s AppyScore™ Blood Test Show 97% Negative Predictive Value For Absence Of Acute Appendicitis In Children And Adolescents Presenting With Abdominal Pain - Business Wire 03.16.12 | 02:03 pm
- Study Demonstrates AspenBio Pharma’s AppyScore Multi-Marker Blood Test Highly Predictive For Absence Of Acute Appendicitis In Children With Abdominal Pain - Business Wire 02.28.12 | 09:02 am
- Rigrodsky & Long, P.A. Announces Class Action Lawsuit Against AspenBio Pharma, Inc. - Business Wire 10.07.10 | 04:10 pm
- The Law Office Of Robbins Umeda LLP Announces The Filing Of A Class Action Suit Against AspenBio Pharma, Inc. - Business Wire 10.07.10 | 04:10 pm
- Investor Notice: The Rosen Law Firm Announces Investigation Of Shareholder Securities Claims Against AspenBio Pharma, Inc. --- APPY - Business Wire 09.03.10 | 08:09 pm
Partner Headlines for APPY
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test - Benzinga 07.19.10 | 04:07 pm
- AspenBio Pharma Shares Plummet on Drug Application Delay - Fox Business 06.07.10 | 04:06 pm
- 4 Small Cap Biotechs To Keep an Eye On - Seeking Alpha 05.26.10 | 04:05 pm
- Thursday Outlook: What, Me Worry? - Seeking Alpha 05.13.10 | 10:05 am
- Biotech CROs Take Center Stage in Recent Deals - Seeking Alpha 05.02.10 | 05:05 am
- Takeover Speculation Swarms at AspenBio Pharma - SeekingAlpha.com 04.26.10 | 03:04 am
- Preview of AspenBio's Potentially Blockbuster Clinical Trials - SeekingAlpha.com 04.25.10 | 08:04 am
- Friday Options Recap - SeekingAlpha.com 04.23.10 | 03:04 pm
- Will AspenBio Pharma Follow in Dendreon and Human Genome Sciences' Footsteps? - SeekingAlpha.com 04.22.10 | 04:04 am
